期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌浸润淋巴细胞对新辅助化学疗法反应的预测及与预后的关系 被引量：1

原文传递
导出
摘要 近年来大量研究认为肿瘤浸润淋巴细胞是宿主免疫系统对肿瘤抗原存在免疫反应的标志,并且可以作为预测乳腺癌患者对蒽环/紫杉类新辅助化学疗法反应的有效指标。在三阴乳腺癌患者中,乳腺癌浸润淋巴细胞可作为一项判断预后的可靠指标。
作者 杨菁 李宏江 羊晓勤
机构地区 四川大学华西医院甲状腺乳腺外科
出处 《华西医学》 CAS 2015年第6期1179-1182,共4页 West China Medical Journal
关键词 乳腺癌 肿瘤浸润淋巴细胞 新辅助化学疗法 预后
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献54

  • 1Desantis C, Ma JM, Bryan L, et al. Breast cancer statistics, 2013[J]. CA Cancer J Clin, 2014, 64(1): 52-62.
  • 2Pernas Simon S. Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications[J]. Ther Adv Med Oncol, 2014, 6(5): 210-221.
  • 3Rampurwala MM, Rocque GB, Burkard ME. Update on adjuvant chemotherapy for early breast cancer[J]. Breast Cancer (Auckl), 2014, 8: 125-133.
  • 4Bhattacharyya T, Sharma SC, Yadav BS, et al. Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: atertiary care centre experience[J]. Indian J Med Paediatr Oncol, 2014, 35(3): 215-220.
  • 5Li Q, Liu M, Ma F, et al. Circulating miR-19a and miR-205 in serum May predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel[J]. PLoS One, 2014, 9(8): e104870.
  • 6Wang K, Deng QT, Liao N, et al. Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy[J]. Tumour Biol, 2013, 34(1): 33-38.
  • 7Yu KD, Liu GY, Zhou XY, et al. Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer[J]. Oncologist, 2012, 17(6): 792-800.
  • 8Tokuda E, Seino Y, Arakawa A, et al. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer[J]. Breast Cancer Res Treat, 2012, 133(2): 427-436.
  • 9Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update[J]. J Clin Oncol, 2006, 24(12): 1940-1949.
  • 10Jones RL, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response[J]. Lancet Oncol, 2006, 7(10): 869-874.

二级参考文献52

  • 1徐林,蒋正刚,李宝华,熊思东.小鼠乳腺癌实验动物模型中CD4^+ CD25^+调节性T细胞的变化及意义[J].复旦学报（医学版）,2006,33(6):736-740. 被引量：13
  • 2Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol,1995;155(3):1151-1164.
  • 3Bach JF.Regulatory T cells under scrutiny.Nat Rev Immunol,2003;3(3):189-198.
  • 4Von Boehmer H.Mechanisms of suppression by suppressor T cells.Nat Immunol,2005;6(4):338-344.
  • 5Joncker NT,Marloie MA,Chernysheva A,et al.Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors.Int J Cancer,2006;118(5):1205-1214.
  • 6Pagès F,Berger A,Camus M,et al.Effector memory T cells,early metastasis,and survival in colorectal cancer.N Engl J Med,2005;353(25):2654-2666.
  • 7Kawaida H,Kono K,Takahashi A.Distribution of CD4^+CD25^high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer.J Surg Res,2005;124(1):151-157.
  • 8Lécureuil C,Combadière B,Mazoyer E,et al.Trapping and apoptosis of novel subsets of memory T lymphocytes expressing CCR6 in the spleen of HIV-infected patients.Blood,2007;109(9):3649-3657.
  • 9Kleinewietfeld M,Puentes F,Borsellino G,et al.CCR6 expression defines regulatory effector/memory-like cells within the CD25^+CD4^+ T-cell subset.Blood,2005;105(7):2877-2886.
  • 10Powell DJ,Rosenberg SA.Phenotypic and functional maturation of tumor antigen-reactive CD8^+ T lymphocytes in patients undergoing multiple course peptide vaccination.J Immunother,2004;27(1):36-47.

共引文献3

同被引文献5

引证文献1

二级引证文献12

华西医学
2015年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部